Pfizer Vaccine Gets FDA Nod

FDA advisors have voted to recommend the emergency use authorization of Pfizer's COVID-19 vaccine, stating that its benefits outweigh the risks. The vote was 17 in favor, 4 against, and 1 abstention. Michelle Cortez, a healthcare reporter, explains the significance of this decision and the expected timeline for FDA's authorization. The vaccine is anticipated to be distributed soon, but logistical challenges such as maintaining cold temperatures and setting up clinics may delay the process. Vaccinations could start by mid-week following the authorization.

What was the outcome of the FDA advisors' vote regarding Pfizer's vaccine?

• No decision made

• Complete rejection

• Unanimous approval

• Majority approval with some dissent

What age group did the FDA advisors recommend the Pfizer vaccine for?

• Only seniors aged 65 and older

• Only adults aged 18 and older

• Everyone aged 16 and older

• Children under 16

What was the main concern among some FDA advisors regarding the vaccine recommendation?

• The vaccine's effectiveness

• The inclusion of 16 and 17-year-olds

• The manufacturing process

• The cost of the vaccine

What is the expected timeline for the FDA to grant emergency use authorization for the Pfizer vaccine?

• No specific timeline

• Within a month

• By the end of the week

• Sometime next year

What logistical challenge is associated with the distribution of the Pfizer vaccine?

• Lack of transportation vehicles

• Shortage of medical staff

• Requirement for very cold storage temperatures

• Insufficient vaccine doses